Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

BOTHELL, Wash. and VANCOUVER, Aug. 4, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an update on current events and activities and announced its second quarter financial results.

Second Quarter 2011 Highlights

  • Expected timing of results from the survival primary endpoint for the custirsen SYNERGY Phase 3 clinical trial remains unchanged at Q4 2013.
  • During discussions regarding the SATURN Special Protocol Assessment, or SPA, amendment, FDA stated that an application supported primarily by the results of SYNERGY alone would be acceptable for submission.
  • We have revised the custirsen SATURN Phase 3 trial protocol to expand the eligible patient population, and to align with the recently approved chemotherapy, cabazitaxel.
  • We are awaiting final, written FDA agreement on the SPA amendment that will allow patients to receive either docetaxel re-treatment or cabazitaxel as second-line chemotherapy.
  • Recruitment efforts are ongoing to enroll more patients in the SATURN study, which has had few patients accrued due to restrictive enrollment criteria regarding docetaxel retreatment and stable pain criteria. Expected timing of results for the pain palliation primary endpoint is now projected to be Q4 2013 rather than Q2 2013.
  • The initiation of the Phase 3 clinical trial evaluating custirsen in patients with non-small cell lung cancer (NSCLC) has been delayed as we determine the optimal chemotherapeutic combination based on safety considerations and the current and evolving standard of care.
  • We believe NSCLC is a promising indication and remain committed to the advancement of custirsen in NSCLC.
  • OGX-427
  • Enrollment continues for both the investigator-sponsored, randomized Phase 2 clinical trial evaluating OGX-427 in patients with castrate-resistant prostate cancer, an
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
    2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
    3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
    4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
    5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
    6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
    8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
    9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
    10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
    11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/2/2015)... , June 26, 2015 Research ... "Vitamin D Market by Analog, Application, End-User & by ... to their offering. This market is projected to ... vitamin D in different applications and rising opportunities in countries ... , Italy , and ...
    (Date:7/2/2015)... July 2, 2015   EVO Aesthetic Center and ... provider for non-invasive aesthetics in Lakeway, Texas ... treatments with the Astanza Duality laser. The medical spa ... through various medical and laser procedures. Their addition of ... a clear solution to their tattoo regret. ...
    (Date:7/2/2015)... 2015 Numotion,s Board of Directors and ... Tamas Feitel has joined the Company as Chief ... highly successful 18 year career at GE serving in ... and productivity to result in significant industry leading growth ... Financial Officer for GE Healthcare Global Services, a $5B ...
    Breaking Medicine Technology:Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Numotion Names Tamas Feitel Chief Financial Officer 2
    ... Timothy Mastro,MD, FACP, DTM&H, who joins Family Health ... Research, will share information on promising,research into pre-exposure ... Conference in Mexico City., Dr. Mastro,s presentation, ... ongoing and upcoming clinical trials that,suggest oral doses ...
    ... Key Thought,Leaders Explore Critical Next Steps for AIDS Vaccine ... NEW YORK, July 28 The following was ... Today, AIDS vaccine research is at a pivotal ... to reach late-stage testing failed.,In the wake of this ...
    Cached Medicine Technology:HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2AIDS Vaccines: Where Do We Go From Here? 2
    (Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... With summer in full swing, Americans are ... is one of the top spots for fishing in the world, and it’s easy to ... of Ontario, Canada has great fish. , Recreational fishing is a huge industry, and ...
    (Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... the most versatile smart light bulbs on the market. , According to the U.S. ...
    (Date:7/2/2015)... ... July 02, 2015 , ... ... of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first introduced, they have ... Their significant popularity has inspired four new, fun shades including: blue, lime, pink ...
    (Date:7/2/2015)... , ... July 02, 2015 , ... Six months ahead ... solo cross-country walk to raise awareness and money for the Pulmonary Hypertension Association ... arrive at PHA’s headquarters near Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday ...
    (Date:7/2/2015)... ... July 02, 2015 , ... ActiveBunch.com recently launched as a social network ... to function as a lifestyle community, Active Bunch allows users to connect with like-minded ... and participate in discussions or group events. , The spokesperson for Active Bunch ...
    Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
    ... ... accepted CoolTouch,s request to re-examine the ,873 Paolini laser lipolysis patent based on prior art ... ... the United States Patent & Trademark Office (USPTO) accepted CoolTouch,s request to re-examine the ,873 ...
    ... ... Hepatitis C and their physicians, caregivers and families, has been redesigned. New features include ... ... The go-to website that provides a wealth of information and news updates about ...
    ... 2 The University HealthSystem Consortium (UHC) today announced ... added to Spend LINK (TM), UHC,s proprietary supply chain ... optimize their pricing and achieve maximum savings. , ... hospital,s expenditure, making it the second largest expense after ...
    ... at Westmead are embarking on a ground-breaking new study ... resistance in overweight adolescents can put the brakes on ... diabetes affects 85 to 90 per cent of all ... younger people and children are increasingly being diagnosed. Often ...
    ... for ,Loose Chains, joins researchers, physicians, neurosurgeons and other brain tumor ... Medical Center , , LOS ... have to work around scheduling conflicts, but Eddie Cleland, drummer for ... to accommodate brain tumor surgery, which was performed by ...
    ... well known to stop or suppress cancer plays a role in ... of Michigan Comprehensive Cancer Center. The researchers found that several pathways ... breast cancer stem cells. Further, by using a drug that ... percent decrease in the number of cancer stem cells within a ...
    Cached Medicine News:Health News:United States Patent and Trademark Office Accepts CoolTouch's Re-examination Request for Cynosure '873 Patent 2Health News:Resource for Those Living with Hepatitis C Announces Website Redesign 2Health News:University HealthSystem Consortium Adds Price Competitive Index to Its Spend Analytics Tool 2Health News:Ground-breaking study to cap the growing trend of type 2 diabetes in overweight adolescents 2Health News:Drummer Eddie Cleland Resumes Life After Brain Surgery and Tells About it at Conference 2Health News:Drummer Eddie Cleland Resumes Life After Brain Surgery and Tells About it at Conference 3Health News:Drummer Eddie Cleland Resumes Life After Brain Surgery and Tells About it at Conference 4Health News:U-M researchers link pathway to breast cancer stem cells 2
    West 2 periosteal elevators....
    Alexander periosteal elevators....
    Sedillot periosteal elevators....
    Modified Freer periosteal elevator, #163, slight curve, 21 cm....
    Medicine Products: